Patents by Inventor Margaret A. Liu

Margaret A. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020032162
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a Th1 type of helper T-cell response (i.e., high IL-2 and IFN-&ggr;). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M.bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Application
    Filed: January 22, 1998
    Publication date: March 14, 2002
    Inventors: JEAN CONTENT, KRIS HUYGEN, MARGARET A. LIU, DONNA MONTGOMERY, JEFFREY ULMER
  • Patent number: 5866553
    Abstract: DNA constructs encoding papilloma virus gene products, capable of being expressed upon direct introduction into animal tissues, are novel prophylactic pharmaceuticals which can provide immune protection against infection by papilloma virus.
    Type: Grant
    Filed: December 17, 1996
    Date of Patent: February 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: John J. Donnelly, Margaret A. Liu, Douglas Martinez, Donna L. Montgomery
  • Patent number: 5736524
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: April 7, 1998
    Assignees: Merck & Co.,. Inc., N. V. Innogenetics S.A.
    Inventors: Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer